UNSPSC 51121924: Proscillaridin

This classification denotes a cardiotonic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KC6BL281EN. European Medicines Agency schedules Proscillaridin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10131MIG. Proscillaridin generally arises in the molecular formula C30H42O8.

UNSPSC 51121924 Proscillaridin, a Commodity code, encompasses cardiac glycoside medications and related pharmaceutical products procured by state and local health and human services agencies, fire departments, and cooperative purchasing alliances for emergency medical services, hospital systems, and health plan administration. State and local buyers under this code acquire branded and generic formulations of proscillaridin and related advanced life support medications for use in emergency response, inpatient care, and pharmacy benefit programs. Issuing bodies include city purchasing departments acting on behalf of fire rescue services, state health and human services commissions managing pharmacy benefit programs, and regional cooperative purchasing alliances serving multiple state and local government jurisdictions. The purchasing mix spans individual emergency medication procurement through competitive sealed bidding, exploratory market-research initiatives through requests for information, and multi-state cooperative purchasing agreements for generic pharmaceutical product lines.

Recent activity appears concentrated in Texas and Minnesota, with scattered municipal procurement in Florida. The City of Tampa Fire Rescue posted an IFB (Bid No. 26-P-00188) on April 24, 2026, for advanced life support medications including epinephrine, labetalol, adenosine, and diltiazem — medications often used alongside or in lieu of proscillaridin in cardiac emergency protocols — with a response deadline of April 8, 2026, and an estimated contract value of $40,000.00 under a one-year term with renewal options and a 5 percent SLBE bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to explore direct-to-manufacturer prescription programs and vendor capabilities for pharmacy benefit delivery across state agencies and self-insured plans, signaling upstream procurement interest in pharmaceutical sourcing and distribution models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed through authorized wholesalers, with proposals due March 26, 2026, and contract effectiveness July 1, 2026, serving participating state and local government facilities across Minnesota and Oregon. The code shows measurable but episodic activity — recent opportunities cluster around fire rescue medication stocks and cooperative purchasing platforms rather than sustained individual vendor relationships.